Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 19/20 | 0.65 |
| ▸ | PDE6C | P51160 | 2/20 | 0.65 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 9/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PDE1A | P54750 | 1/20 | 0.45 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.45 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19518053 | 0.94 | PDE5A (0.66) | PDE5APDE6CPDE3BPDE3AHDAC1 | |
| SCHEMBL30917339 | 0.92 | PDE5A (0.62) | PDE5APDE6CPDE3BPDE3AHDAC1 | |
| SCHEMBL2032429 | 0.91 | PDE5A (0.78) | PDE5APDE6CPDE3BPDE3AHDAC1 | |
| SCHEMBL28482244 | 0.88 | PDE5A (0.83) | PDE5APDE6CPDE3BPDE3AHDAC1 | |
| SCHEMBL28473221 | 0.85 | PDE5A (0.70) | PDE5APDE6CPDE3BPDE3AHDAC1 | |
| SCHEMBL5964550 | 0.85 | PDE5A (0.70) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| SCHEMBL2032052 | 0.84 | PDE5A (0.74) | PDE5APDE6CHDAC1HDAC6HDAC2 | |
| Lodenafil SCHEMBL18416781 | 0.84 | PDE5A (0.78) | PDE5APDE6CPDE3BPDE3AHDAC1 | |
| SCHEMBL25013469 | 0.81 | PDE5A (0.85) | PDE5APDE6CPDE3BPDE3AHDAC1 | |
| SCHEMBL29357402 | 0.81 | PDE5A (0.85) | PDE5APDE6CPDE3BPDE3AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9833456-B2 | Treatment of erectile dysfunction and other indications | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-9833456-B2 | Treatment of erectile dysfunction and other indications | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170027942-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-20170027942-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2017-02-02 | — | — | US | disclosed |
| US-9498482-B2 | Treatment of erectile dysfunction and other indications | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-9498482-B2 | Treatment of erectile dysfunction and other indications | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2016-11-22 | — | — | US | disclosed |
| US-20160263120-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160263120-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | STRATEGIC SCIENCE & TECHNOLOGIES, LLC (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160263120-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE6C 21/4885PDE3B 5/4885 |
| US-20170027942-A1 | TREATMENT OF ERECTILE DYSFUNCTION AND OTHER INDICATIONS | PDE5A, PDE3A, PDE12 | PDE5A 1/4885PDE6C 21/4885PDE3B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.